KRAS and neoplasm: The concordance of KRAS mutation was higher between PPE and paired neoplasia samples (EAH and carcinoma, 13/18, 72.22%) compared with normal (16/48, 33.33%) and hyperplasia tissues (1/7, 14.29%, P < 0.01, Table 3).